Phase 2 Failure – Talk Bio

Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study

1 month ago talkbio0Tagged Biosciences, Clinical Trials, depression drug, Depressive disorder, Drug licensing, NBI-1070770, Neurocrine, pharmaceutical setbacks, Phase 2 Failure, psychiatry pipeline, Takeda

Neurocrine Biosciences; Takeda; NBI-1070770; Phase 2 failure; major depressive disorder; depression drug; psychiatry pipeline; clinical trial results; drug licensing; pharmaceutical setbacks

UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure

12 months ago talkbio0Tagged Drug Development, Novartis, Parkinson 's disease, Phase 2 Failure, UCB

UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

1 year ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.